Omnicell, Inc. $OMCL Shares Bought by Perbak Capital Partners LLP

Perbak Capital Partners LLP lifted its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 55.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 40,827 shares of the company’s stock after buying an additional 14,573 shares during the period. Perbak Capital Partners LLP owned about 0.09% of Omnicell worth $1,243,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Raymond James Financial Inc. acquired a new position in Omnicell during the second quarter worth $26,000. First Horizon Corp acquired a new stake in Omnicell in the third quarter valued at $31,000. Farther Finance Advisors LLC lifted its holdings in Omnicell by 784.8% in the third quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company’s stock valued at $36,000 after acquiring an additional 1,036 shares during the period. LSV Asset Management purchased a new stake in shares of Omnicell during the 3rd quarter worth $97,000. Finally, Tower Research Capital LLC TRC boosted its position in shares of Omnicell by 385.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company’s stock worth $146,000 after purchasing an additional 3,932 shares in the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Corey J. Manley sold 6,106 shares of the stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $49.90, for a total value of $304,689.40. Following the sale, the executive vice president directly owned 91,674 shares in the company, valued at $4,574,532.60. This represents a 6.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.52% of the stock is owned by company insiders.

Omnicell Trading Down 2.0%

Shares of OMCL stock opened at $34.40 on Friday. The stock has a market cap of $1.56 billion, a P/E ratio of 860.22, a P/E/G ratio of 1.26 and a beta of 0.79. The company has a quick ratio of 1.22, a current ratio of 1.43 and a debt-to-equity ratio of 0.14. Omnicell, Inc. has a fifty-two week low of $22.66 and a fifty-two week high of $55.00. The business has a fifty day simple moving average of $43.76 and a 200-day simple moving average of $38.43.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, February 5th. The company reported $0.40 EPS for the quarter, missing the consensus estimate of $0.47 by ($0.07). The business had revenue of $313.98 million during the quarter, compared to analysts’ expectations of $313.36 million. Omnicell had a return on equity of 3.00% and a net margin of 0.17%.Omnicell’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.60 earnings per share. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. On average, analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Weiss Ratings downgraded shares of Omnicell from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, March 2nd. KeyCorp raised shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective on the stock in a report on Wednesday, January 7th. UBS Group set a $60.00 target price on shares of Omnicell and gave the stock a “buy” rating in a research report on Friday. Benchmark reaffirmed a “buy” rating on shares of Omnicell in a report on Friday. Finally, Wall Street Zen downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $55.29.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.